Abstract: The present invention relates to a medical use of a compound, of Chemical Formula 1, for treating, alleviating or preventing non-alcoholic steatohepatitis (NASH) and/or hepatic fibrosis.
Type:
Grant
Filed:
July 19, 2019
Date of Patent:
June 18, 2024
Assignee:
J2H BIOTECH INC.
Inventors:
Jae-Sun Kim, Hyung-Chul Ryu, Jee-Woong Lim, Jung-Gun Joung, Sun-Joo Kim, Yeon-Woo Son, Hyung-Jun Kim, Wenling Song
Abstract: The present invention relates to a novel compound and a medicinal use of the novel compound. In particular, the present invention relates to a novel compound useful for the treatment and/or prevention of muscular dystrophy, including Duchenne muscular atrophy, and a medicinal use of the novel compound.
Type:
Grant
Filed:
December 24, 2019
Date of Patent:
November 1, 2022
Assignee:
J2H BIOTECH INC.
Inventors:
Hyung-Chul Ryu, Jae-Sun Kim, Jee-Woong Lim, Ju-Young Lee, Wenling Song, Tae-Gon Kim
Abstract: The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of neurodegenerative and/or motor neuron disease.
Type:
Grant
Filed:
September 9, 2019
Date of Patent:
August 30, 2022
Assignee:
J2H BIOTECH INC.
Inventors:
Jae-Sun Kim, Hyung-Chul Ryu, Jee-Woong Lim, Eun-Bi Kang, Hyuk-Min Kim, Hyunjun Yang, Dukho Chang, Dong-Gyu Kim, Byung Hwan Ryoo, Yong-Ho Oh